Accelerate Your
Cell & Gene Therapy
Contract Development & Manufacturing
Accelerate Your
Cell & Gene Therapy
Contract Development & Manufacturing
At NecstGen, we enable the next generation of therapies by offering development support and GMP production of Cell and Gene Therapies. Together, we challenge today’s possibilities and enable the unthinkable.
The Scientist behind HEK293
While working in the Netherlands in the 1970s, genetic engineer and virologist Frank Graham developed the Calcium Phosphate Transfection technique and created the HEK293 cell line, now a cornerstone of gene therapy, vaccine development, and viral vector production.
Are you bringing a Gene or Cell therapy to patients? We can help.
Solely dedicated to the field of Cell and Gene Therapy, we provide capacity, expertise, and services tailored accelerate the development of your therapy to the clinic and beyond. Our approach is characterised by open and transparent communication, fostering a culture of collaboration and knowledge sharing.
Cell Therapies
NecstGen offers services for Cell Therapy and Ex vivo Cell Therapy process and analytical development and manufacturing.
Viral Vectors
NecstGen provides a high-caliber process for Viral Vector manufacturing for your Gene Therapy.
Cleanroom Rental
NecstGen offers flexible GMP Cleanroom Rental at a state-of-the-art facility.
Consultancy & Support
At NecstGen, we support academic and industrial therapy developers in advancing Cell and Gene Therapies from concept to clinical reality. With our expertise on analytical and process development and manufacturing, we consult therapy developers allowing informed decision-making throughout all stages of therapy development .
“At NecstGen, we offer process development solutions, contract preclinical/ GMP manufacturing and cleanroom rental for Cell and Gene Therapies to clinicians, academic, small, medium, and large commercial organisations worldwide. We have a focused expert team and bespoke facility to offer you the support and capacity needed to deliver your therapy to patients.
We enable the next generation of therapies by translating research programs into health solutions for patients.”
News & Insights
Webinar Replay: Bioreactor Scale-up Principles for Viral Vector Production
Bioreactor Scale-up Principles for Viral Vector Production Scaling viral vector production from...
NecstGen Contributing to the Future of CGT
24 April 2026, the Cell & Gene Therapy Community Gathers at PLNT Leiden for Sharp Discussions, Hands-on Workshops, and Practical Insights from Active CGT Programmes.
Accelerating the Translation of iPSCs from Research to Clinical Application
An Interview with Catalina Gomez-Puerto, Senior Scientist
